Member Info for Jarv55

They are working on two new products
The third element was to conduct a strategic review of RMS and its three very disparate subsidiaries. The Board's initial findings are that the value of P2F, as the Company's largest and most significant subsidiary, resides principally in its intellectual property and the expertise of its scientific team, led by Dr Gareth Cave. The original inclusion of copper nano-particles in a non-woven layer for the P2F masks has led to the development of two other products, also utilising the natural anti-viral properties of copper, with significant long-term target markets.

The agreement with Francis McIntyre Limited, as announced on 4 March 2021, has experienced administrative delays in meeting the listing criteria of the e-commerce platform and in registering the product's ProLarva brand name. The former is expected to be complete shortly although the latter may take another couple of months to work through the UK's Intellectual Property Office. The result is that Francis McIntyre Limited has not been in a position to place any further orders beyond the initial 100,000 masks. However, this is expected to change once the listing criteria has been approved. Don't understand this at all regarding the listing not clear.

Numed Holdings Limited (www.numed.co.uk), who will supply the P2F mask into GP, dental and veterinary surgeries, opticians and care homes across the UK and Ireland. Although the strong interest displayed in 2020 in P2F's anti-viral technology has yet to translate into significant sales of the ProLarva mask in 2021, P2F is currently in discussions with several potential large customers both in the UK and overseas and hopes to be able to announce some significant orders in the near future.

They are in ongoing discussions with large customers

They are focusing on areas that are not price sensitive is that abroad?
With the manufacturing chain falling into place, P2F is now in a position to increase its sales and marketing efforts. As prices of imported generic masks that do not contain P2F's patented anti-viral layer have fallen significantly over the last year, P2F is focusing more on specific sectors where demand is less price sensitive and more concerned with the unique utility and value of P2F's ProLarva MHRA approved, anti-viral mask. The Company is pleased to announce that it has entered into a distribution agreement with Numed Holdings Limited (www.numed.co.uk), who will supply the P2F

so lets break this down and read between the lines the machine they bought is still not running properly but they are near fixing this they now have a deal Volz
n order to be able to meet potential demand, P2F sought to outsource some of its manufacturing through an agreement with Volz Filters ("Volz"). Heads of terms have been agreed by both companies, which will move to a more formal agreement once the sales pipeline is firmed up. In the meantime, Volz is manufacturing anti-viral masks for P2F on an order-by-order basis. Discussions have also progressed with the manufacturer of the alpha-virion layer (the specific layer containing P2F's nano-particles) and P2F is confident that it now has a smooth running, high-quality supply chain; from the in-house production of nano-particles to the outsourced production of the alpha-virion layer to both the in-house and outsourced production of the P2F mask itself.

You can buy at xo.com online £5.95 per trade

You can buy it on XO.com online for £5.95 AJ Bell and HL I believe also list it.

https://www.bbc.co.uk/news/uk-56964296

Disagree with the fraud comments don't see any value in cloudville or Gyro just want them to get these masks out there to produce revenues asap there are plenty of tenders they could go for. They need a good marketing team and a Ceo with drive.

Come on folks the guy forgot it was a bank holiday hopefully we will get some news next week. Can't be long now.

Thunks that is a shame selling at the bottom

This will be a streamlined process since it is understood the UK application can bridge to the EU approval.



Manufacturing scale up and commercial discussions continue to progress well and the Company looks forward to updating shareholders further in the coming months.



The prevalence of ED disrupts the lives of at least 1 in 5 men globally, with around 23 million men in the US and 20 million men in the UK, France, Italy and Germany. There has been little innovation in ED treatments for over ten years and many patients continue to suffer dissatisfaction with existing treatments.



James Barder, Chief Executive of Futura Medical commented: "Today marks a transformational milestone for the Company. We are excited to be able to offer MED3000 to millions of patients in Europe as the first, clinically proven OTC treatment for erectile dysfunction. MED3000 is a highly differentiated product, with a rapid speed of onset addressing significant unmet needs, across all patient severities in the $5.6 billion global ED market. We look forward to further MED3000 marketing approvals in the coming years in multiple regions across the world, including the USA and Asia."



Professor David Ralph, Consultant Urologist at University College London and past president of the European Society of Sexual Medicine commented on the approval: "The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events. With topical application, it will be of particular appeal to patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs. It can also potentially be used in conjunction with other ED products to improve overall efficacy to patients. As such the product will be of great interest to the medical community."

30 April 2021

Futura Medical Receives Approval from EU Notified Body for MED3000

Breakthrough, fast acting topical gel formulation MED3000 becomes Europe's first approved clinically proven, topical treatment for erectile dysfunction available without the need of a doctor's prescription



Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces that further to the announcement of 19 March 2021, the Company has now received its MDR EU Quality Management Certificate for the placing on the market of a Class II(b) medical device known as MED3000 ("CE mark approval").



Futura's breakthrough, fast acting topical gel formulation MED3000, is the first clinically proven, pan-European topical treatment for adult men with erectile dysfunction ("ED") available without a doctor's prescription ("OTC").



Studies have shown MED3000 to be an extremely effective treatment for ED with an excellent safety profile. MED3000 has a unique evaporative mode of action which the Company believes stimulates nerve endings in the glans ***** to cause an erection. MED3000 helps men get an erection within 10 minutes, substantially faster than oral tablet phosphodiesterase-5 inhibitors (PDE5i's), with significant benefits for spontaneous rather than pre-planned sexual intercourse.



The CE mark approval of MED3000 from the EU Notified Body paves the way for approval in many countries around the world, including in the Middle East, Africa, the Far East and Latin American regions which allow "fast-track" review based on recognition of the EU CE mark. Due to post-Brexit arrangements, the EU CE mark can be used to market the product in Great Britain until 30 June 2023 by which time a specific UKCA mark has to be obtained.

Will be interesting to see what stateside makes of the news this afternoon

This is going to move up soon https://invst.ly/un3q5

https://www.lse.co.uk/rns/VAST/baita-plai-revised-mine-plan-investor-presentation-e2zezl5a9uqft7s.html
Will be interesting to see the increase in revenues as Copper rises.

https://www.cnbc.com/2021/04/14/goldman-says-copper-is-the-new-oil-raises-price-forecast.html?utm_campaign=Metal%20Insights%20Campaign&utm_content=163912562&utm_medium=social&utm_source=twitter&hss_channel=tw-1073333434406318090

https://twitter.com/Jarvy55/status/1387763226864148481?s=20

mannnan well said

tryying to break the bull flag might back test first we will see but someone is defo buying these dips
https://invst.ly/umqsp